HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Early suppression of striatal cyclic GMP may predetermine the induction and severity of chronic haloperidol-induced vacous chewing movements.

Abstract
Haloperidol persists in brain tissue long after discontinuation while haloperidol-induced tardive dyskinesia often worsens after withdrawal of the drug. The mechanism of haloperidol-associated tardive dyskinesia is unknown, although neurotoxic pathways are suspected. Nitric oxide (NO) synthase (NOS) inhibitors exacerbate haloperidol-induced catalepsy, while haloperidol itself is a potent neuronal NOS inhibitor in vitro. Since NO and cGMP are involved in striatal neural plasticity, this study investigates a possible relation between cGMP and extrapyramidal symptoms as early predictors of haloperidol-associated tardive dyskinesia. Sprague-Dawley rats were administered either water or oral haloperidol (0.25 mg/kg/d p.o.) for 17 weeks, followed by 3 weeks withdrawal. Saline (i.p.) or the nNOS/guanylate cyclase inhibitor, methylene blue (5 mg/kg/d i.p.), were co-administered with haloperidol for the first three weeks of treatment. Vacous chewing movements (VCM's) were continuously monitored, followed by the determination of striatal cGMP and peripheral serum nitrogen oxide (NOx) levels. Chronic haloperidol engendered significant VCM's, with acute withdrawal associated with significantly reduced striatal cGMP levels as well as reduced serum NOx. Furthermore, suppressed cGMP levels were maintained and VCM's were significantly worse after early administration of methylene blue to the chronic haloperidol group. However, serum NOx was unchanged from control. We conclude that the central effects of chronic haloperidol on striatal NO-cGMP function persist for up to 3 weeks post-withdrawal. Moreover, suppression of striatal cGMP constitutes an early neuronal insult that determines the presence and intensity of haloperidol-associated motor dysfunction.
AuthorsA M Bester, B H Harvey
JournalMetabolic brain disease (Metab Brain Dis) Vol. 15 Issue 4 Pg. 275-85 (Dec 2000) ISSN: 0885-7490 [Print] United States
PMID11383552 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Dopamine Antagonists
  • Enzyme Inhibitors
  • Nitric Oxide
  • Cyclic GMP
  • Haloperidol
  • Methylene Blue
Topics
  • Animals
  • Chronic Disease
  • Corpus Striatum (metabolism)
  • Cyclic GMP (metabolism)
  • Dopamine Antagonists (pharmacology)
  • Dyskinesia, Drug-Induced (metabolism)
  • Enzyme Inhibitors (pharmacology)
  • Extrapyramidal Tracts (metabolism)
  • Haloperidol (pharmacology)
  • Male
  • Mastication
  • Methylene Blue (pharmacology)
  • Motor Activity (drug effects)
  • Nitric Oxide (metabolism)
  • Rats
  • Rats, Sprague-Dawley

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: